While the current bill reauthorizing US FDA user fees seems to be a done deal in Congress, the Trump White House continues to insist medical products industries pick up the entire tab for reviewing drugs, biosimilars and devices.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?